OmniAb Appoints Steve Love to its Board of Directors
01 Novembre 2023 - 2:00PM
Business Wire
OmniAb, Inc. (NASDAQ: OABI) today announced the
appointment of Steve Love to its Board of Directors. Mr. Love has
more than 30 years of financial experience including more than 13
years serving in Chief Financial Officer positions, and will serve
on OmniAb’s Audit Committee as Chair. With this appointment the
OmniAb Board returns to seven directors, including five independent
directors.
“We are delighted Steve has agreed to join the OmniAb Board of
Directors and extend a warm welcome,” stated John Higgins, OmniAb
Board Chair. “Steve’s vast financial expertise, technical knowledge
and experience leading technology and biotechnology companies will
be valuable assets as we grow and expand our business. We look
forward to leveraging his financial insights and deep transactional
knowledge to further drive OmniAb’s strategy and success.”
“My industry experiences have ranged from machine learning and
AI-enabled software to biotechnology and therapeutics, and I am
excited to bring that insight to OmniAb’s cutting-edge
technologies,” stated Mr. Love. “Matt Foehr and the OmniAb team
have built a best-in-class suite of proprietary transgenic animals,
screening and other technologies that create an exciting growth
engine for the future. I look forward to partnering with executive
management and the Board as we advance our business strategy.”
Mr. Love is currently the Chief Financial Officer of Heap Inc.,
a leading machine learning-enabled digital analytics software
company. Prior to Heap, Mr. Love spent nearly 30 years in finance
leading the growth strategy and data-driven decision making at
Juniper Square Inc., Dialpad Inc., Mblox Inc., Affymax, Inc. and
Connetics Corporation, among other companies. As a financial
leader, Mr. Love has overseen more than $750 million in fundraising
from top-tier venture capital firms, led buy- and sell-side M&A
transactions totaling more than $2 billion in transaction value,
and been responsible for worldwide teams across finance, legal,
data analytics, facilities and human resources. He began his career
at Ernst & Young LLP supporting private and public
biotechnology and software companies.
Mr. Love holds a Masters in Accounting and a B.S. in Accounting
from the University of Southern California, and is a Certified
Public Accountant in California (inactive).
About OmniAb®
OmniAb’s discovery platform provides pharmaceutical industry
partners access to diverse antibody repertoires and high-throughput
screening technologies to enable discovery of next-generation
therapeutics. At the heart of the OmniAb platform is the Biological
Intelligence™ (BI) of our proprietary transgenic animals, including
OmniRat®, OmniChicken® and OmniMouse® that have been genetically
modified to generate antibodies with human sequences to facilitate
development of human therapeutic candidates. OmniFlic® (transgenic
rat) and OmniClic® (transgenic chicken) address industry needs for
bispecific antibody applications through a common light chain
approach, and OmniTaur™ features unique structural attributes of
cow antibodies for complex targets. We believe the OmniAb animals
comprise the most diverse host systems available in the industry
and they are optimally leveraged through computational antigen
design and immunization methods, paired with high-throughput single
B cell phenotypic screening and mining of next-generation
sequencing datasets with custom algorithms to identify fully human
antibodies with superior performance and developability
characteristics. These proprietary technologies are joined with and
leverage OmniDeep™, which is a suite of in silico tools for
therapeutic discovery and optimization that are woven throughout
OmniAb’s various technologies and capabilities. Additionally, an
established core competency focused on ion channels and
transporters further differentiates OmniAb’s technology and creates
opportunities in many emerging target classes. OmniAb antibodies
have been leveraged across modalities, including bispecific
antibodies, antibody-drug conjugates and others.
The OmniAb suite of technologies span from BI-powered repertoire
generation to cutting-edge antibody discovery and optimization
offering a highly efficient and customizable end-to-end solution
for the growing discovery needs of the global pharmaceutical
industry.
For more information, please visit www.omniab.com.
Forward-Looking Statements
OmniAb cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. Words such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “intend,” “target,”
“project,” “contemplates,” “believes,” “estimates,” “predicts,”
“potential” or “continue” and similar expressions, are intended to
identify forward-looking statements. The forward-looking statements
are based on our current beliefs and expectations and include
statements regarding the potential growth of our business based on
our platform of technologies. Actual results may differ from those
set forth in this press release due to the risks and uncertainties
inherent in our business, including, without limitation: our future
success is dependent on acceptance of our technology platform and
technologies by new and existing partners, as well as on the
eventual development, approval and commercialization of products
developed by our partners for which we have no control over the
development plan, regulatory strategy or commercialization efforts;
biopharmaceutical development is inherently uncertain; risks
arising from changes in technology; the competitive environment in
the life sciences and biotechnology platform market; our failure to
maintain, protect and defend our intellectual property rights;
difficulties with performance of third parties we will rely on for
our business; regulatory developments in the United States and
foreign countries; unstable market and economic conditions may have
serious adverse consequences on our business, financial condition
and stock price; and other risks described in our prior press
releases and filings with the SEC, including under the heading
“Risk Factors” in the our annual report on Form 10-K and any
subsequent filings with the SEC. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof, and we undertake no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary
statement, which is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231101823948/en/
OmniAb, Inc. Neha Singh, Ph.D. investors@OmniAb.com X (Twitter)
@OmniAbTech (510) 768-7760
Grafico Azioni OmniAb (NASDAQ:OABI)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni OmniAb (NASDAQ:OABI)
Storico
Da Ott 2023 a Ott 2024